

## AMENDMENTS TO THE SPECIFICATION

Page 9, after line 24, after BRIEF DESCRIPTION OF THE DRAWINGS,  
please amend as follows:

Fig. 1 is a graph of murine bone marrow stem cell proliferation and Fig. 2 is a graph of NO production in murine macrophage cells;

Figs. 3, 4 and 5 are graphs of Dextran-FITC conjugate take up by human dendritic cells differentiated from monocytes isolated from peripheral blood;

Fig 6 is a graph of CD40 ~~co-stimulating~~ surface marker expression from human dendritic cells;

Figs. 7, 8 and 9 are graphs of CD86, CD83 and CD80 ~~co-stimulating~~ surface marker expression, respectively, from human dendritic cells;

Fig. 10 is a graph ~~Figs. 10, 11 and 12 are graphs of OM-294-MP and OM-294-DP effects of  $\alpha$  TNF- $\alpha$  production by predendritic cells at DC-6 stage; in supernatants of human dendritic cells culture;~~

Fig. 11 is a graph of OM-294-MP and OM-294-DP on IL12 p70 production by predendritic cells at DC-6 stage;

Fig. 12 is a graph of the effect of OM-294-MP on IL12 p70 production in the supernatant fluid of monocytes;

Figs. 13, 14 and 15 are graphs of ELISA 2, 3 and 4 weeks after the first, second and third immunization of mice with a malaria antigen( the synthetic peptide Pb CS His6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite;

Fig. 16 is a graph of antibody titer before and after immunization of mice with a malaria antigen ( the synthetic peptide Pb CS His-6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite;

Figs. 17 to 20 are graphs of ELISPOT IFN- $\gamma$  IFN producing lymphocytes after immunization of mice a malaria antigen( with the synthetic peptide Pb CS His-6 242-310 amino acid sequence of Plasmodium bergei circum sporozoite; and

Fig. 21 is an ~~electrophoretogram~~ electropherogram;

Figs. 22 to 29 are graphs of specific mouse antibodies IgG1, IgG2a, IgM directed to specific ~~agents~~ antigens;

Figs. 30(a) and 30(b) are graphs of anti-gp63 ~~anti-gp63~~ immune response and Figs. 31(a) and 31(b) are graphs of lymph node lymphocyte response;

Figs. 32(a) and 32(b) are graphs of anti-LmCPb immune response;

~~Figs. 33, 34 and 35 are outlines of various processes of the invention~~

Figs. 33 to 38 are schemes outlining the synthetic processes of the invention;

Figs. 39 to 41 are ~~graphs of ES MS~~ Mass spectra of the compounds of the invention;

Fig. 42 and 43 are ~~graphs of~~  $^1\text{H}$ -NMR spectra of the compounds of the invention;

Figs 44 and 45 ~~are graphs of~~  $^{13}\text{C}$ -NMR spectra of the compounds of the invention;

Fig. 46 ~~is a graph~~ and 47 are  $^{31}\text{P}$ -NMR spectra of the compounds of the invention.